1 / 40

Plasma cell Disorders

Plasma cell Disorders. S. Sami Kartı, MD, Prof. Plasma cells. Terminally differentiated cells of B-lymphocyte lineage Produce antibodies Normal plasma cells are incapable of dividing. Classification of plasma cell disease. Multiple myeloma Variants Non-secretory myeloma Indolant myeloma

terrel
Download Presentation

Plasma cell Disorders

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Plasma cell Disorders S. Sami Kartı, MD, Prof.

  2. Plasma cells • Terminally differentiated cells of B-lymphocyte lineage • Produce antibodies • Normal plasma cells are incapable of dividing

  3. Classification of plasma cell disease • Multiple myeloma • Variants • Non-secretory myeloma • Indolant myeloma • Smoldering myeloma • Plasma cell leukemia

  4. Classification of plasma cell diseases • Plasmocytoma • Solitary plasmocytoma • Multiple plasmocytoma • Primary amyloidosis • POEMS Syndrome • Waldenström’s Macroglobulinemia • Heavy Chain Diseases

  5. Multiple Myeloma

  6. Definition • B-cell malignancy characterised by abnormal proliferation of plasma cells able to produce a monoclonal immunoglobulin (M protein)

  7. Incidence • 3-9 cases per 100,000 population/y • more frequent in elderly • modest male predominance

  8. Clinical forms of MM • Multiple myeloma • Non-secretory myeloma • Smoldering myeloma • Plasma cell leukemia

  9. M-protein (paraprotein) • Seen in 99% of cases in serum and/or urine • IgG > 50% • IgA 20-25% • IgE and IgD 1-3% • light chain 20% • 1% of cases are nonsecretory

  10. Clinical manifestations are related to malignant behavior of plasma cells • and abnormalities produced by M protein

  11. plasma cell proliferation • multiple osteolytic bone lesions • Hypercalcemia • bone marrow suppression ( pancytopenia ) • monoclonal M protein • decreased level of normal immunoglobulins • hyperviscosity

  12. Symptoms • Bone pains • Weakness and fatigue • Weight loss

  13. Laboratory • ESR > 100 • anaemia, thrombocytopenia • rouleaux in peripheral blood smears • marrow plasmacytosis • hyperproteinemia • hypercalcemia • proteinuria • azotemia

  14. Causes of renal failure in MM • Hyperviscosity • Hypercalcemia • Hyperuricemia • Light chain deposition • Analgesic nephropathy

  15. Evaluation for a suspected MM • Serum and urine protein electrophoresis • Serum and urine immunofixation and immunglobulin quantitation • Radiographic skeletal survey • Bone marrow examination

  16. Protein electrophoresis in a MM patient

  17. Rouloux formation in peripheral smear

  18. Lytic lesions in cranial x-ray

  19. Bone marrow aspiration and biyopsy in a MM patient

  20. Bone marrow aspiration of a MM patient

  21. Immunohistochemistry in MM

  22. Immunohistochemistry in MM

  23. Diagnostic Criteria for Multiple Myeloma • Major criteria • I. Plasmacytoma on tissue biopsy • II. Bone marrow plasma cell > 30% • III. Monoclonal M spike on electrophoresis IgG > 3,5g/dl,IgA>2g/dl, light chain>1g/dl in 24h urinsample • Minor criteria • a. Bone marrow plasma cells 10-30% • b. M spike but less than above • c. Lytic bone lesions • d. Normal IgM < 50mg, IgA < 100mg, IgG < 600mg/dl Minimum of 1 major and 1 minor or 3 minor criteria including A and B

  24. Staging of Multiple Myeloma Clinical staging • is based on level of haemoglobin, serum calcium, immunoglobulins and presence or not of lytic bone lesions • correlates with myeloma burden and prognosis I. Low tumor mass II. Intermediate tumor mass III. High tumor mass • subclassification A - creatinine < 2mg/dl B - creatinine > 2mg/dl

  25. Poor prognosis factors • Cytogenetical abnormalities of 11 and 13 chromosomes • Beta-2 microglobulin > 2,5 ug/ml

  26. Treatment • Patients <65-70 years • Velcade + Deksametazon • Thalidomid • VAD (Vincristin, Adriamycin, Dexamethasone) • high-dose therapy with autologous stem cell transplantation • allogeneic stem cell transplantation ( conventional and „mini”) • Patients >65 years • conventional chemotherapy

  27. Treatment • Conventional chemotherapy • Velcade + dekasametazon • Talidomid • VAD (Vincristin, Adriamycin, Dexamethasone) • Melphlan + Prednisone • M2 ( Vincristine, Melphalan, Cyclophosphamid, BCNU, Prednisone) • Response rate 50-60% patients • Long term survival 5-10% patients

  28. Treatment • Autologous transplantation • patients < 65-70 years • treatment related mortality 10-20% • response rate 80% • long term survival 40-50%

  29. Treatment • non-myeloablative therapy and allogeneic transplantation

  30. Treatment • Supportive treatment • biphosphonates, calcitonin • recombinant erythropoietin • immunoglobulins • plasma exchange • radiation therapy

  31. Monoclonal gammopathy of undetermined significance ( MGUS) • M protein presence, stable • levels of M protein: IgG<3,5g IgA<2g,ligh chain<1g/day • normal immunoglobulins - normal levels • marrow plasmacytosis < 5% • complete blood count - normal • no lytic bone lesions • no signs of disease

  32. Monoclonal gammopathy of undetermined significance ( MGUS) • M protein • 3% of people > 70 years • 15% of people > 90 years • 10% of patients with MGUS develop multiple myeloma

  33. Diagnostic criteria for smoldering myeloma • Same as MGUS except: • Serum M-component at myeloma levels • Marrow plasmocytosis 10-30%

  34. Plasma cell leukemia

  35. Plasma cell leukemia • >2x109 plasma cells in peripheral blood • Younger age • Higher incidence of organomegaly and lymphadenopathy • More extensive bone marrow infiltration • Poor response to chemotherapy

  36. Non-secretory myeloma • 1% of multiple myeloma • No serum or urine monoclonal protein • Must rule out IgD and IgE myeloma

  37. Waldenström’s Macroglobulinemia • Monoclonal protein is IgM • No lytic lesions • Hyperviscosity (headache, tinnitus, dizziness, somnelence, etc) • Bone marrow aspiration reveals lymphoplasmocytic cells

  38. Bone marrow aspiration and biopsy in WM

  39. Solitary plasmacytoma • Localized plasma cell tumor • Absence of plasma cell infiltrate in bone marrow biyopsy • No evidence of other lytic lesions on radiographic examination • Absence of renal failure, anemia or hypercalcemia

  40. Osteosclerotic Myeloma(POEMS Syndrome) • Polyneuropathy • Organomegaly (hepatomegaly, LAP) • Endocrinopathy (hypogonadism, hypoyhtroidism) • Monoclonal gammopathy • Skin changes (hyperpigmentation)

More Related